Modified Form of Common Flu Virus may Help Treat Pancreatic Cancer

by Rishika Gupta on  January 25, 2018 at 12:50 PM Research News
RSS Email Print This Page Comment bookmark
Font : A-A+

Pancreatic cancer growth may now be targeted with a modified version of common flu virus finds a new study. The findings of this study are published in the Molecular Cancer Therapeutics journal.
Modified Form of Common Flu Virus may Help Treat Pancreatic Cancer
Modified Form of Common Flu Virus may Help Treat Pancreatic Cancer

The study suggests that the new technique could potentially become a promising new treatment for patients with the aggressive disease, and could be combined with existing chemotherapy to improve chances of survival.

Show Full Article


First author Dr. Stella Man from Barts Cancer Institute at Queen Mary said: "We've shown for the first time that pancreatic cancers can be specifically targeted with a modified version of the common flu virus.

"The new virus specifically infects and kills pancreatic cancer cells, causing few side effects in nearby healthy tissue. Not only is our targeting strategy both selective and effective, but we have now further engineered the virus so that it can be delivered in the bloodstream to reach cancer cells that have spread throughout the body.

"If we manage to confirm these results in human clinical trials, then this may become a promising new treatment for pancreatic cancer patients, and could be combined with existing chemotherapy drugs to kill persevering cancer cells."

Each year around 9,800 people in the UK are diagnosed with pancreatic cancer. The disease is particularly aggressive and has the lowest survival rate of all cancers - fewer than five percent of patients diagnosed survive for five years or more.

The reasons behind the poor survival rates include late diagnosis of the disease and cancer's rapid development of resistance to current therapies. To avoid drug resistance, the use of mutated viruses has emerged as a promising new strategy for attacking cancers in a more targeted way.

The research, published in the journal Molecular Cancer Therapeutics, took advantage of a unique feature of pancreatic cancer cells - the presence of a specific molecule called alpha v beta 6 (αvβ6), which is found on the surface of many pancreatic cancer cells but, crucially, not on normal cells.

The team modified the common flu virus to display an additional small protein on its outer coat that recognizes and binds to αvβ6-molecules. Once the virus enters the cancer cell, the virus replicates, producing many copies of itself prior to bursting out of the cell and thereby destroying it in the process. The newly released viral copies can then bind to neighboring cancer cells and repeat the same cycle, eventually removing the tumor mass altogether.

The researchers tested the viruses on human pancreatic cancer cells, which had been grafted onto mice, and found that they inhibited cancer growth.

The concept of using modified viruses has previously shown promising results in various cancers including brain, head and neck, and prostate. The researchers say that their new virus is more specific and efficacious than previous viral versions, and has the added advantage of being able to co-operate with chemotherapy drugs that are currently used in the clinic.

The flu virus is further modified so that it is unable to cause disease in healthy individuals.

Maggie Blanks, CEO of Pancreatic Cancer Research Fund said: "It's exciting to see the research we've funded at Barts Cancer Institute since 2009 - both in modifying viruses as a potential treatment for pancreatic cancer and progressing knowledge about alpha v beta 6 - come together in this study with such positive results. Developing more effective treatments for pancreatic cancer becomes more urgent every year as the incidence of the disease increases, and we hope to see this research progressed further."

As with all potential new therapies, advancement towards human clinical trials will require more time as lead researcher Dr. Gunnel Halldén, from Barts Cancer Institute at Queen Mary, explains: "Currently, we are seeking new funds to support further development into clinical trials within the next two years. With this funding in place, early phase trials will usually take about five years to determine whether or not the therapy is safe and effective."

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Recommended Reading

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Premium Membership Benefits

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive